S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

NBIX Neurocrine Biosciences Inc

140.71

0.88 (0.63%)

04 May 2024 - Closed

Delayed by 15 minutes

Confidential Treatment Order (ct Order)

Neurocrine Biosciences (NASDAQ:NBIX)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Neurocrine Biosciences Charts.

Neurocrine Biosciences (NASDAQ:NBIX)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Neurocrine Biosciences Charts.

Neurocrine Biosciences Inc News

Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
Saturday 4 May 2024 (2 days ago) • PR Newswire (US)

Neurocrine Biosciences Reports First Quarter 2024 Financial Results
Wednesday 1 May 2024 (4 days ago) • PR Newswire (US)

Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
Wednesday 1 May 2024 (5 days ago) • PR Newswire (US)

Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
Wednesday 24 April 2024 (2 weeks ago) • PR Newswire (US)

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Tuesday 23 April 2024 (2 weeks ago) • PR Newswire (US)

Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
Wednesday 17 April 2024 (3 weeks ago) • GlobeNewswire Inc.

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
Thursday 11 April 2024 (4 weeks ago) • PR Newswire (US)

Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
Wednesday 3 April 2024 (1 month ago) • PR Newswire (US)

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Thursday 28 March 2024 (1 month ago) • PR Newswire (US)

Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
Tuesday 12 March 2024 (2 months ago) • PR Newswire (US)

Form 144 - Report of proposed sale of securities
Saturday 9 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Saturday 9 March 2024 (2 months ago) • Edgar (US Regulatory)

More Neurocrine Biosciences Inc News Articles

Commonwealth Bank Of Aus...

National Australia Bank

Australia And New Zealan...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions